Epoetin alfa--focus on dialyzability. Case study of the anemic patient.
Epoetin alfa therapy has typically been administered at the end of dialysis. A recently completed in vivo study with a small patient population strengthens previous study findings and suggests that this protein can be safely administered during high-flux dialysis without fear of membrane adsorption. Data indicate that successful use of this technique depends on a variety of factors, including the site of administration. If confirmed, these findings could benefit both patients and clinicians.
Keen
M L
ML
D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D016903:Drug Monitoring; D004921:Erythropoietin / Q000378:metabolism* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D006435:Renal Dialysis
D004921:Erythropoietin